Cardiotoxicity is rarely observed during cisplatin chemotherapy. A possible synergistic toxic effect of cisplatin with etoposide on cardiac electrical activity is discussed. A case of a 60-year-old woman with squamous cell lung carcinoma who developed paroxysmal supraventricular tachycardia during cisplatin chemotherapy is reported. The potential cardiotoxicity should be considered when cisplatin is combined with other cardiotoxic agents or used in patients with cardiac disease.
O'ConnelT.X., BerenbaumM.C.: Cardiac and pulmonary effects of high doses of cyclophosphamide and isophosphamide.Cancer. Res., 34: 1586–1591, 1974.
18.
SchechterJ.P., JonesS.E.: Myocardial infarction in a 27-year-old woman: possible complication of treatment with VP16-213 (NSC-141540), mediastinal irradiation or both.Cancer Chemother. Rep., 59: 887–888, 1979.
19.
SchmollH.: Review of etoposide single agent activity.Cancer Treat. Rev., 9(suppl. A): 21–30, 1982.
20.
ShaeppiU., HeymanI.A., FleischmanR.W.: Cis-diamminedichloroplatinum (II) preclinical evaluation of intravenous injection in dogs, monkeys and mice.Toxicol. Appl. Pharmacol., 25: 230, 1973.
21.
SomersG., AbramovM., WittekM., NaetsJ.P., Myocardial infarction: a complication of vincristine treatment.Lancet, 1: 690, 1976.
22.
StevensonD.L., MikhailidisD.P., GilletD.S.: Cardiotoxicity of 5-fluorouracil.Lancet:2: 406–407, 1977.
23.
TalleyR.S., O'BryanR.M., GuttermanJ.A., Brown-leeR.W., McCredieK.B.: Clinical evaluation of toxic effects of cis-diamminedichloroplatinum (NSC-119875). Phase I clinical study.Cancer Chemother. Rep., 57: 465–471, 1973.
WeissA.J., ManthelR.W.: Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule with particular reference to lack of cardiac toxicity.Cancer, 40: 2046–2052, 1977.
28.
WiltshawE., CarrB.: Cis-diamminechlorideplati-num (II). In: Platinum Coordination Complexes in Cancer Chemotherapy, ConnorsRoberts (eds.), pp. 178–182, Springer-Verlag, Heidelberg, 1974.
